Miruvor
Sign up
The short answer

What studies of Clarithromycin (Biaxin) found

3papers on Clarithromycin (Biaxin)
12people in 2 studies testing Clarithromycin (Biaxin) alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, the randomised trial (very low certainty): 2 findings, all D.

2 outcomes rated · see each below

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty), for pain.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, studies found little or no difference with Clarithromycin (Biaxin). For ME/CFS, Clarithromycin (Biaxin) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 3 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Clarithromycin (Biaxin) · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Clarithromycin (Biaxin) · Long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Breathlessness1 study · 11 people took Clarithromycin (Biaxin) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 34 people found no clear difference; a small benefit can't be ruled out.

The randomised trial34 randomised · four weeks · 500 mg, twice daily for four weeks

No clear difference in breathlessness.

The evidence is very uncertain about the effect of clarithromycin (Biaxin) on breathlessness in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 34 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Efficacy of Hydroxychloroquine versus Clarithromycin in the Improvement of Dyspnea and Cough in Patients after the Treatment of Acute-Phase COVID-19 (2023)

    People in the study
    34 randomised
    Dose
    500 mg, twice daily for four weeks
    Outcome
    FVC Forced vital capacity
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Daily life and health overall

Daily functioning1 study · 11 people took Clarithromycin (Biaxin) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 34 people found no clear difference; a small benefit can't be ruled out; effect size 0.65 (moderate).

The randomised trial34 randomised · four weeks · 500 mg, twice daily for four weeks

No clear difference in daily functioning.

The evidence is very uncertain about the effect of clarithromycin (Biaxin) on daily functioning in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 34 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.65 (moderate)

How big was the difference?

0.65, moderate. The effect size compares Clarithromycin (Biaxin) with hcq.

See the 1 study
  1. Efficacy of Hydroxychloroquine versus Clarithromycin in the Improvement of Dyspnea and Cough in Patients after the Treatment of Acute-Phase COVID-19 (2023)

    People in the study
    34 randomised
    Dose
    500 mg, twice daily for four weeks
    Outcome
    6MW 6-min walk (6MW) test
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

ME/CFS

Pain1 study · 1 (few people) person took Clarithromycin (Biaxin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).

Studies with no comparison group1 in the study · 500mg daily (few people)

Pain improved.

The evidence is very uncertain about the effect of clarithromycin (Biaxin) on pain in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
See the 1 study
  1. Clarithromycin for the Relief of Pain in a Patient with Chronic Fatigue Syndrome and Fibromyalgia: A Case Report (2013)

    People in the study
    1 in the study
    Dose
    500mg daily
    Outcome
    generalized pain
    Effect
    better
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    500 mg at the start

  2. 2Top dose

    Most often 500 mg (2 of 2 studies)

All papers

  1. Efficacy of Hydroxychloroquine versus Clarithromycin in the Improvement of Dyspnea and Cough in Patients after the Treatment of Acute-Phase COVID-192023 · randomised trial · 34 randomised
    Summary

    This study enrolled 34 patients aged 20-50 years in the recovery phase of COVID-19 who still had symptoms such as shortness of breath, cough, and pulmonary involvement on CT two weeks after treatment ended at Rasool Akram Hospital, Tehran, Iran. Patients were divided into three groups: HCQ 200 mg twice daily for four weeks (n=12), clarithromycin 500 mg twice daily for four weeks (n=11), and placebo similar to the last two groups (n=11). Patients were followed two and four weeks after starting treatment. Dyspnea and cough were assessed with the Medical Research Council and visual analog scale (VAS), with laboratory tests, 6-min walk test, and spirometry also checked. After treatment, VAS cough was 0.76 with HCQ, 0.02 with clarithromycin, and 1.15 with placebo; clarithromycin versus placebo had SMD -1.02 (95% CI -1.90 to -0.11; P=0.080), reported as not statistically significant. HCQ versus clarithromycin had SMD 0.67 (95% CI -0.18 to 1.50; P=0.29). Patients receiving HCQ had a 64% chance of reducing shortness of breath versus placebo (RR=0.36); clarithromycin had a 40% lower chance (RR=0.60). FVC was 80.81, 78.34, and 81.32; FEV1 was 90.47, 90.57, and 90.47, with no differences observed. 6MW was 583.77, 635.88, and 585.46 meters. The text does not report side effects or withdrawals. Authors state a small sample size, single center, and limited resources hindered follow-up.

  2. Clarithromycin for the Relief of Pain in a Patient with Chronic Fatigue Syndrome and Fibromyalgia: A Case Report2013 · case report · 1 in the study
    Summary

    This case report describes one 36-year-old woman with fibromyalgia and a 15-year history of chronic fatigue syndrome at a tertiary academic medical center outpatient MSK clinic. She was started on Lyrica, Trazodone, and physical therapy; Lyrica was later discontinued and she was started on low-dose Naltrexone. She was placed on Clarithromycin again, 500mg daily; no comparison group was reported. The paper reports that she had noted significant improvement of her generalized pain while taking Clarithromycin, and that the pain returned when it was stopped. The report also states that her fatigue has not completely resolved, that she now only takes Advil for pain occasionally, rest and ice, and that she sleeps about 8 hours per night. Harms were not reported; withdrawals for harms were not reported. The authors conclude that Clarithromycin seemed to play a role in the relief fibromyalgia-associated pain in a patient who also had chronic fatigue syndrome. They do not state limitations.

  3. Severe ME in Children.2020 · combination: given with other treatments
    Summary

    The paper presents a series of case reports of individual cases to illustrate clinical presentation and general principles of management of severe paediatric ME/CFS. The author writes that there is very limited data on patients who are very severe, housebound or bedbound. No number of patients, clinic setting, comparison group or formal outcome measures are reported. Treatments described across the cases include nasogastric or nasojejunal tube feeding, intramuscular immunoglobulin monthly for 12 months, amitriptyline, carbamazepine, clarithromycin, doxycycline, opiates, a urinary catheter, active physiotherapy for three months and Tender Loving Care. The paper reports that one case made a very slow recovery, with tube feeding stopped after 3 years, and was operating at 95% of normal 20 years later; another made a full recovery by the end of two years; another recovered completely within 12 months after clarithromycin was changed to doxycycline and had no relapses at follow up 12 years later; and Case A made a full spontaneous recovery. Case B received active physiotherapy for three months, deteriorated further and remained severely affected 20 years later. Case C died. Harms include a traumatic hospital experience, a convulsive myoclonic jerk from noise and sensory overload. The author states that one should not draw too many conclusions from one case.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime